Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01578707
Registration number
NCT01578707
Ethics application status
Date submitted
11/04/2012
Date registered
17/04/2012
Date last updated
18/12/2019
Titles & IDs
Public title
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Query!
Scientific title
A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Query!
Secondary ID [1]
0
0
2012-000694-23
Query!
Secondary ID [2]
0
0
PCYC-1112-CA
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
RESONATE™
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Relapsed or Refractory Chronic Lymphocytic Leukemia
0
0
Query!
Small Lymphocytic Lymphoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Query!
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Cancer
0
0
0
0
Query!
Children's - Leukaemia & Lymphoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - ofatumumab
Treatment: Drugs - ibrutinib
Active comparator: Ofatumumab (Arm A) - An anti-CD20 monoclonal antibody
Experimental: ibrutinib (Arm B) - A Bruton Tyrosine Kinase Inhibitor
Treatment: Drugs: ofatumumab
The ofatumumab (IV) dosage and schedule is 12 doses administered over 24 weeks or until disease progression, unacceptable toxicity.
Week 1: 300 mg initial dose Week 2 through 8: 2,000 mg (once weekly) Week 12, 16, 20 and 24: 2,000 mg (every 4 weeks)
Treatment: Drugs: ibrutinib
ibrutinib 420 mg (3 x 140-mg capsules) will be administered orally once daily until disease progression or unacceptable toxicity
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
PFS (Progression Free Survival) by Independent Review Committee (IRC), Limited to the Time of Primary Analysis 06 November 2013
Query!
Assessment method [1]
0
0
The primary objective of this study was to evaluate the efficacy of ibrutinib compared to ofatumumab based on independent review committee (IRC) assessment of progression-free survival (PFS) according to 2008 IWCLL guidelines.
Query!
Timepoint [1]
0
0
Analysis was conducted after observing approximately 117 PFS events, which occurred about 18 months after the first subject was enrolled.
Query!
Secondary outcome [1]
0
0
Overall Response Rate (ORR) by Independent Review Committee (IRC)
Query!
Assessment method [1]
0
0
Overall Response Rate per the IWCLL 2008 criteria as assessed by IRC, limited to the time of primary analysis 06 November 2013
Query!
Timepoint [1]
0
0
About 18 months after the first subject was enrolled
Query!
Secondary outcome [2]
0
0
OS (Overall Survival)
Query!
Assessment method [2]
0
0
OS analysis was conducted at the time of study closure, with no adjustment for crossover from the ofatumumab arm to the ibrutinib arm
Query!
Timepoint [2]
0
0
OS analysis was conducted at the time of study closure, including up to 6 years of study follow-up
Query!
Secondary outcome [3]
0
0
Rate of Sustained Hemoglobin and Platelet Improvement
Query!
Assessment method [3]
0
0
Proportion of subjects with hemoglobin (HgB) increase \>=20 g/L and platelet (PLT) increase \>=50% over baseline continuously for \>=56 days without blood transfusions or growth factors.
Query!
Timepoint [3]
0
0
From study initiation to study closure, including up to 6 years of study follow-up
Query!
Eligibility
Key inclusion criteria
* ECOG performance status of 0-1.
* Diagnosis of CLL or SLL that meets IWCLL 2008 criteria.
* Active disease meeting at least 1 of the IWCLL 2008 criteria for requiring treatment.
* Must have received at least one prior therapy for CLL/SLL.
* Considered not appropriate for treatment or retreatment with purine analog based therapy.
* Measurable nodal disease by CT.
* Patients must be able to receive outpatient treatment and laboratory monitoring at the institution that administers study drug for the entire study.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Known CNS lymphoma or leukemia.
* No documentation of cytogenetic and/or FISH in patient records prior to first dose of study drug.
* Any history of Richter's transformation or prolymphocytic leukemia.
* Uncontrolled Autoimmune Hemolytic Anemia (AIHA) or idiopathic thrombocytopenia purpura (ITP).
* Prior exposure to ofatumumab or to ibrutinib.
* Prior autologous transplant within 6 months prior to first dose of study drug.
* Prior allogeneic stem cell transplant within 6 months or with any evidence of active graft versus host disease or requirement for immunosuppressants within 28 days prior to first dose of study drug.
* History of prior malignancy, with the exception of certain skin cancers and malignancies treated with curative intent and with no evidence of active disease for more than 3 years.
* Serologic status reflecting active hepatitis B or C infection.
* Unable to swallow capsules or disease significantly affecting gastrointestinal function.
* Uncontrolled active systemic fungal, bacterial, viral, or other infection.
* History of stroke or intracranial hemorrhage within 6 months prior to the first dose of study drug.
* Requires anticoagulation with warfarin.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/06/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
25/10/2018
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
391
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
Site # 500 - St. Leonards
Query!
Recruitment hospital [2]
0
0
Site # 503 - Brisbane
Query!
Recruitment hospital [3]
0
0
Site # 199 - East Melbourne
Query!
Recruitment hospital [4]
0
0
Site # 501 - Fitzroy
Query!
Recruitment hospital [5]
0
0
Site # 502 - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2065 - St. Leonards
Query!
Recruitment postcode(s) [2]
0
0
4102 - Brisbane
Query!
Recruitment postcode(s) [3]
0
0
3002 - East Melbourne
Query!
Recruitment postcode(s) [4]
0
0
3109 - Fitzroy
Query!
Recruitment postcode(s) [5]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Connecticut
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Georgia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Indiana
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Massachusetts
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Michigan
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Minnesota
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New Jersey
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New York
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Ohio
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Pennsylvania
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
South Carolina
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Tennessee
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Texas
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Virginia
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Washington
Query!
Country [17]
0
0
Austria
Query!
State/province [17]
0
0
Graz
Query!
Country [18]
0
0
Austria
Query!
State/province [18]
0
0
Linz
Query!
Country [19]
0
0
Austria
Query!
State/province [19]
0
0
Salzburg
Query!
Country [20]
0
0
Austria
Query!
State/province [20]
0
0
Vienna
Query!
Country [21]
0
0
Austria
Query!
State/province [21]
0
0
Wein
Query!
Country [22]
0
0
Austria
Query!
State/province [22]
0
0
Wels
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Antwerpen
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Argenteuil
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Bobigny
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Bordeaux
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Caen
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Clermont Ferrand
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Marseille
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Nantes
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Rennes
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Vandœuvre-lès-Nancy
Query!
Country [33]
0
0
Ireland
Query!
State/province [33]
0
0
Dublin
Query!
Country [34]
0
0
Ireland
Query!
State/province [34]
0
0
Galway
Query!
Country [35]
0
0
Italy
Query!
State/province [35]
0
0
Milano
Query!
Country [36]
0
0
Italy
Query!
State/province [36]
0
0
Modena
Query!
Country [37]
0
0
Italy
Query!
State/province [37]
0
0
Padova
Query!
Country [38]
0
0
Poland
Query!
State/province [38]
0
0
Gdansk
Query!
Country [39]
0
0
Poland
Query!
State/province [39]
0
0
Lodz
Query!
Country [40]
0
0
Spain
Query!
State/province [40]
0
0
Barcelona
Query!
Country [41]
0
0
Spain
Query!
State/province [41]
0
0
Coruna
Query!
Country [42]
0
0
Spain
Query!
State/province [42]
0
0
Madrid
Query!
Country [43]
0
0
Spain
Query!
State/province [43]
0
0
Pamplona
Query!
Country [44]
0
0
United Kingdom
Query!
State/province [44]
0
0
Essex
Query!
Country [45]
0
0
United Kingdom
Query!
State/province [45]
0
0
Surrey
Query!
Country [46]
0
0
United Kingdom
Query!
State/province [46]
0
0
Bournemouth
Query!
Country [47]
0
0
United Kingdom
Query!
State/province [47]
0
0
Canterbury
Query!
Country [48]
0
0
United Kingdom
Query!
State/province [48]
0
0
Cardiff
Query!
Country [49]
0
0
United Kingdom
Query!
State/province [49]
0
0
Headington
Query!
Country [50]
0
0
United Kingdom
Query!
State/province [50]
0
0
Leeds
Query!
Country [51]
0
0
United Kingdom
Query!
State/province [51]
0
0
Liverpool
Query!
Country [52]
0
0
United Kingdom
Query!
State/province [52]
0
0
London
Query!
Country [53]
0
0
United Kingdom
Query!
State/province [53]
0
0
Nottingham
Query!
Country [54]
0
0
United Kingdom
Query!
State/province [54]
0
0
Southampton
Query!
Country [55]
0
0
United Kingdom
Query!
State/province [55]
0
0
Withington
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Pharmacyclics LLC.
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Janssen Research & Development, LLC
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of the study is to evaluate whether treatment with ibrutinib as a monotherapy results in a clinically significant improvement in progression free survival (PFS) as compared to treatment with ofatumumab in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Query!
Trial website
https://clinicaltrials.gov/study/NCT01578707
Query!
Trial related presentations / publications
Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019 Dec;94(12):1353-1363. doi: 10.1002/ajh.25638. Epub 2019 Oct 13. Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O'Brien SM. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019 Jun 25;3(12):1799-1807. doi: 10.1182/bloodadvances.2018028761. Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019 May 9;133(19):2031-2042. doi: 10.1182/blood-2018-08-870238. Epub 2019 Mar 6. O'Brien SM, Jaglowski S, Byrd JC, Bannerji R, Blum KA, Fox CP, Furman RR, Hillmen P, Kipps TJ, Montillo M, Sharman J, Suzuki S, James DF, Chu AD, Coutre SE. Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol. 2018 May 1;4(5):712-716. doi: 10.1001/jamaoncol.2017.5604. Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017 Oct;102(10):1796-1805. doi: 10.3324/haematol.2017.171041. Epub 2017 Jul 27. Barr PM, Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jaeger U, Furman RR, Cymbalista F, Montillo M, Dearden C, Robak T, Moreno C, Pagel JM, Burger JA, Suzuki S, Sukbuntherng J, Cole G, James DF, Byrd JC. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017 May 11;129(19):2612-2615. doi: 10.1182/blood-2016-12-737346. Epub 2017 Apr 3. Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol. 2015 Apr;1(1):80-7. doi: 10.1001/jamaoncol.2014.218. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Anita Szoke, MD
Query!
Address
0
0
Pharmacyclics LLC.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/07/NCT01578707/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/07/NCT01578707/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01578707
Download to PDF